Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 29, 2026

Back to today

Another Haircut with Avy the Barber

SoFi’s stock case hinges on interest rates, tangible book value and private-credit loan sales after its $1.5 billion equity offering.

SOFI $22B
WHAT ARE WE DOING? “Contrarians At The Gate” 3 clicks

From X

@BrokenMoats 6 clicks

Broken Moats on X

$BSP really have to question Gregg as the right to choice to lead Berkshire with this BSP investment. While it's meaningless in size to Berkshire, it's what it says about the investment process under Gregg and how they are underwriting managers. This does not strike me as a Buffet investment on any level. Something to watch as he continues to deploy capital....not sure how you get comfortable with an acquisition roll up of intangible assets, especially against the unknown of ai disruption. They should go back and study the intangible asset roll ups from the prior decade in the pharma space
@kevin__mak 4 clicks

Kevin Mak on X

I believe there's a high % chance $QURE gets its approval. Stuff like this from the FDA, in my eyes, further strengthens that belief. They want to generally make the review criteria more clear, more patient (advocacy) focused, and more flexible about what evidence is reasonably attainable. Not lenient for the sake of being reckless, but because there are situations that warrant different criteria. I think it would be quite incongruent to be vocally advocating for these new policies (which are suspiciously similar to the QURE debacle), while simultaneously crushing a high-profile drug approval like AMT-130. Incongruent doesn't mean it can't happen, just that it seems like the tail outcome. "The new framework is intended to enable patient input at earlier stages and at milestones throughout the development and review process. It also aims to provide greater clarity and consistency to drug developers on regulatory decision making. The agency said in a statement that it should take into account what evidence is reasonably attainable, given the nature of rare diseases." To be clear, FDA officials denied that the initiative was motivated by the earlier controversies. The connection to AMT-130, and the positive read-through, is my interpretation. "In an interview, senior officials at the agency denied that the initiative had anything to do with the earlier controversies" --- Disclosure: Creek Drive and its affiliated funds holds positions in QURE. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Investor Letters

All letters

CoStar: 3Q26 Business Recap

CoStar’s 3Q26 revenue growth slowed to 14% as bookings fell to $37 million, while cost cuts lifted EBIT margin to 8.8%.

CSGP $13B
Speedwell Memos 3 clicks

ServiceNow Q3 FY12/26 Earnings Review

ServiceNow’s Q3 revenue rose 20.5% to $4.11 billion, while non-GAAP EPS missed consensus and fourth-quarter cRPO growth guidance slowed to…

NOW $110B
Cestrian Capital Research 2 clicks

Meta: A Clearer Roadmap

Meta's non-cancelable commitments reached $455 billion as FY26 capex approaches $140 billion, driving expense growth and 700-basis-point…

META $1.6T
TSOH Investment Research 3 clicks

Why So Much Copper?

Amphenol and other copper-connectivity suppliers benefit as copper remains essential inside AI racks, where low-voltage, high-current power…

APH $196B
Jimmy's Journal 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

288 firms

Sectors

Ordered by how often our editor reaches for them.